CervoMed filed a prospectus related to an offer and resale of 10.08M shares of common stock by selling stockholders. The filing details the proposed transaction involving the equity shares.

Transaction Details

The prospectus outlines the specifics of the offer, including the number of shares and the parties involved in the resale.

CervoMed Inc., a clinical-stage biotechnology company, announced that five presentations at the Alzheimer's Association International Conference (AAIC) 2026 will feature data on neflamapimod, its drug candidate for dementia with Lewy bodies (DLB). The conference is scheduled in London from July 12-15, 2026. The presentations will explore the drug's impact on disease progression, neurodegeneration biomarkers, and optimal dosing strategies.

DLB is the second most common progressive dementia after Alzheimer’s disease, characterized by cognitive decline, visual hallucinations, and motor symptoms. There are currently no approved treatments in the United States or European Union. Neflamapimod is an oral small molecule designed to inhibit p38α kinase, targeting neuroinflammation and synaptic dysfunction.

Clinical Presentations

The AAIC sessions will include findings from the RewinD-LB Phase 2 trial and other studies. Key topics include the effect of neflamapimod on basal forebrain atrophy, plasma drug exposure-response relationships, and clinical worsening rates in patients with specific biomarker profiles.

Trial Data and Development Path

Data from the 91-patient Phase 2a AscenD-LB trial indicated that neflamapimod significantly improved dementia severity and functional mobility. The 159-patient Phase 2b RewinD-LB trial, a 16-week randomized, double-blind, placebo-controlled study followed by a 32-week open-label extension, showed improvements in cognitive and functional outcomes. Benefits were most pronounced in patients without Alzheimer’s disease co-pathology.

In November 2025, CervoMed announced alignment with the FDA on a potential registration path for neflamapimod in DLB. The company is currently focused on identifying a strategic partner to advance the drug into a Phase 3 trial. Additionally, CervoMed completed enrollment in a Phase 2a trial for non-fluent variant primary progressive aphasia (nfvPPA), with interim biomarker data expected in the early fourth quarter of 2026.